Charu Aggarwal/pc3i.upenn.edu
Jun 1, 2025, 07:55
ASCO 2025 Science in Seconds: Charu Aggarwal on How a Molecular Assay May Help Identify People with NSCLC
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“Check out our ASCO 25 Science in Seconds!
Dr. Charu Aggarwal discusses how a molecular assay may help identify people with NSCLC who could benefit from adj. chemotherapy.
Learn more.”
Title: An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay
Journal: ASCO, Journal of Clinical Oncology
Authors: David Spigel, Virginie Westeel, Ian Anderson, Laurent Greillier, Florian Guisier, Olivier Bylicki, Firas Badin, Gaelle Rousseau-Bussac, Clotilde Deldycke, Frank Griesinger, Adam Bograd, Wangjian Zhong, Matthew Gubens, John Crowley, Heiko von der Leyen, Gavitt Woodard, Johannes Kratz, David Jablons, Michael Mann
More posts featuring Charu Aggarwal on OncoDaily.
Adam Bograd
American Society of Clinical Oncology
ASCO
ASCO 2025
Charu Aggarwal
Clotilde Deldycke
David Jablons
David Spigel
Firas Badin
Florian Guisier
Frank Griesinger
Gaelle Rousseau-Bussac
Gavitt Woodard
Heiko von der Leyen
Ian Anderson
Johannes Kratz
John Crowley
Laurent Greillier
Matthew Gubens
Michael Mann
molecular assay
NSCLC
Olivier Bylicki
Science in Seconds
Virginie Westeel
Wangjian Zhong
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 18:07
Jun 2, 2025, 18:00
Jun 2, 2025, 17:43
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20